Download full-text PDF |
Source |
---|
BMJ Open
March 2025
Institute for Health Research, University of Bedfordshire Faculty of Health and Social Sciences, Luton, UK.
Objectives: To explore the barriers to conversations about deceased organ donation among adults living in the UK.
Design: Systematic review with narrative synthesis.
Data Sources: PubMed, MEDline via OVID, APA PsycInfo via EBSCO, Web of Science via Clarivate and Scopus via Elsevier, covering studies that were published between January 2006 and December 2023.
Open Forum Infect Dis
December 2024
Institute for Infection and Immunity, St George's, University of London, London, United Kingdom.
Background: Hepatitis B virus (HBV) infection is a significant cause of morbidity and mortality globally. The World Health Organization estimates that just 10.5% of individuals living with HBV globally are aware of their status.
View Article and Find Full Text PDFJ Infect Dev Ctries
February 2025
Centro de Investigación sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Mexico.
Introduction: Dengue is currently the most widespread vector-borne disease, and its transmission has been intensively studied in endemic/hyperendemic localities. However, to obtain a complete picture of dengue transmission, it is necessary to study nonendemic localities. Imported dengue cases have been reported in Mexico City, and the presence of eggs of the vector Aedes aegypti has been detected.
View Article and Find Full Text PDFFront Pain Res (Lausanne)
February 2025
Département des Sciences de la Santé, Université du Québec en Abitibi-Témiscamingue (UQAT), Rouyn-Noranda, QC, Canada.
Introduction: Excessive polypharmacy, which can be defined as the concurrent use of ≥10 medications, is prevalent among individuals with chronic pain. However, it remains unclear how it may vary between individuals or over time.
Objectives: This study aimed to describe and identify factors associated with trajectories of excessive polypharmacy.
Lancet Reg Health West Pac
March 2025
School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Background: Several domestically-manufactured nonavalent HPV vaccine candidates are in phase III clinical trials and their future availability may address the current dilemma of insufficient supply and high price of the overseas-manufactured nonavalent HPV vaccine in China. We compare the population-level effectiveness and cost-effectiveness of switching to nonavalent HPV vaccination in China.
Methods: We used a previously validated transmission model to project the lifetime costs and effectiveness of five same-vaccine and two mixed-vaccine strategies.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!